scholarly journals Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases

Oncotarget ◽  
2014 ◽  
Vol 5 (23) ◽  
pp. 12440-12447 ◽  
Author(s):  
Zoran Gatalica ◽  
Sherri Z. Millis ◽  
Semir Vranic ◽  
Ryan Bender ◽  
Gargi D. Basu ◽  
...  
Keyword(s):  
Drug Response ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Site Analysis ◽  
Tumor Profiling

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

2013 ◽  
Vol 31 (2) ◽  
pp. 217-223 ◽  
Author(s):  
John D. Hainsworth ◽  
Mark S. Rubin ◽  
David R. Spigel ◽  
Ralph V. Boccia ◽  
Samuel Raby ◽  
...  
Keyword(s):  
Median Survival ◽  
Prospective Trial ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Specific Therapy ◽  
Site Specific ◽  
Tissue Of Origin ◽  
Tumor Types ◽  
Tumor Profiling

Purpose Molecular tumor profiling is a promising diagnostic technique to determine the tissue of origin in patients with carcinoma of unknown primary site (CUP). However, the clinical value of these molecular predictions is unknown. We used tumor profiling results to direct site-specific therapy for patients with CUP. Patients and Methods Tumor biopsy specimens from previously untreated patients with CUP were tested with a 92-gene reverse transcriptase polymerase chain reaction cancer classification assay. When a tissue of origin was predicted, patients who were treatment candidates received standard site-specific first-line therapy. Results Of 289 patients enrolled, 252 had successful assays performed, and 247 (98%) had a tissue of origin predicted. Sites most commonly predicted were biliary tract (18%), urothelium (11%), colorectal (10%), and non–small-cell lung (7%). Two hundred twenty-three patients were treatment candidates, and 194 patients received assay-directed site-specific treatment. In these 194 patients, the median survival time was 12.5 months (95% CI, 9.1 to 15.4 months). When the assay predicted tumor types that were clinically more responsive, the median survival was significantly improved when compared with predictions of more resistant tumors (13.4 v 7.6 months, respectively; P = .04). Conclusion In this large prospective trial, molecular tumor profiling predicted a tissue of origin in most patients with CUP. The median survival time of 12.5 months for patients who received assay-directed site-specific therapy compares favorably with previous results using empiric CUP regimens. Patients with CUP predicted to have more responsive tumor types had longer survival compared with patients with less responsive tumor types. Molecular tumor profiling contributes to the management of patients with CUP and should be a part of their standard evaluation.

Molecular tumor profiling (MTP) in cancer of unknown primary site (CUP): A complement to standard pathologic diagnosis.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 10560-10560 ◽  
Author(s):  
D. S. Thompson ◽  
J. D. Hainsworth ◽  
C. M. Lane ◽  
W. J. Lennington ◽  
D. R. Spigel ◽  
...  
Keyword(s):  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Pathologic Diagnosis ◽  
Tumor Profiling

scholarly journals Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site

2021 ◽  
Author(s):  
Xinrong Li ◽  
Yan Shao ◽  
Liqiang Sheng ◽  
Junquan Zhu ◽  
Zeming Wang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Primary Site ◽  
Unknown Primary ◽  
Tumor Site ◽  
Metastatic Adenocarcinoma ◽  
Unknown Primary Site

scholarly journals Baseline Staging of Melanoma with Unknown Primary Site: The Value of Serum S100 Protein and Positron Emission Tomography

Dermatology ◽  
2008 ◽  
Vol 217 (4) ◽  
pp. 351-355 ◽  
Author(s):  
Patrick A. Oberholzer ◽  
Mirjana Urosevic ◽  
Hans C. Steinert ◽  
Reinhard Dummer
Keyword(s):  
Positron Emission Tomography ◽  
S100 Protein ◽  
Primary Site ◽  
Emission Tomography ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Positron Emission ◽  
Baseline Staging
Sign in / Sign up

Export Citation Format

Share Document